ProQR (PRQR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 13. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the stock and has a $12.00 price target.
Andrew Fein’s rating is based on the promising potential of ProQR’s Axiomer technology, particularly in addressing the unmet medical needs in Primary Sclerosing Cholangitis (PSC). The company’s lead program, AX-0810, is entering Phase 1 trials, with expectations of significant data readouts by the fourth quarter of 2025. The focus on RNA editing for genetically validated diseases, coupled with the severe lack of approved treatments for PSC, positions ProQR favorably.
Fein highlights several factors supporting the Buy rating: the recognized importance of bile acids in PSC, preclinical data showing promising changes in bile acid uptake, and the enhanced potency and stability of the next-generation AX-0810. Additionally, the potential for a good safety profile and the encouraging biomarker data further strengthen the case. These elements, along with a reevaluation of market penetration assumptions, have led to an increased price target from $10 to $12.
Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Neurocrine, and Vertex Pharmaceuticals. According to TipRanks, Fein has an average return of 2.5% and a 40.69% success rate on recommended stocks.
In another report released on March 14, Raymond James also reiterated a Buy rating on the stock with a $14.00 price target.